Alnylam Pharmaceuticals Q4 2023 Adj EPS $(0.77) Beats $(1.32) Estimate, Sales $346.00M Miss $442.90M Estimate
Portfolio Pulse from Benzinga Newsdesk
Alnylam Pharmaceuticals (ALNY) reported Q4 2023 adjusted EPS of $(0.77), surpassing the $(1.32) estimate. However, its sales of $346.00M fell short of the $442.90M estimate, marking a 21.88% miss but a 3.27% increase from the previous year.
February 15, 2024 | 1:02 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Alnylam Pharmaceuticals reported better-than-expected Q4 2023 EPS but missed sales estimates, showing mixed financial performance.
The better-than-expected EPS could be seen positively by investors, indicating efficient cost management or higher profitability than anticipated. However, the miss on sales estimates could raise concerns about revenue growth and market demand for ALNY's products. The mixed results present a neutral short-term impact as positive EPS performance may offset concerns from lower sales.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100